Small Cap Feast

28th February 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 


Delistings:
DP Eurasia N.V (DPEU.L) has left the Premium Listing of the London Stock Exchange



Whats baking in the oven?

Potential Initial Public Offerings:

Media speculation—Shein, the fashion retailer from China, is considering the possibility of switching its IPO from New York to London because of the hurdles to listing in the U.S. Chancellor Jeremy Hunt has met with the company. The company was reportedly valued at $66bn as part of share sale in 2023.


Reverse Takeovers:


Change of Market:


Banquet Buffet

AB Dynamics £18.50 £424.3m (ABDP.L)
The designer, manufacturer and supplier of testing, simulation and measurement products to the global transport market, issues a pre-close trading update for the six-month period ending 29 February 2024. The Group expects to deliver revenue growth of c. 5% to c. £51m. Net cash at 29 February 2024 expected to be c. £27m after the final deferred consideration payment of £5.7m for the acquisition of Ansible Motion. ABD Solutions continues to make good progress, with several full-scale commercial opportunities for the Indigo Drive retrofit automation system in the near-term pipeline. The Board expect that FY2024 performance is unchanged.

Animalcare Group 225p £135.2m (ANCR.L)
The international animal health business, announces that it has disposed of its majority shareholding in Identicare Ltd (Identicare) to BG Bidco 21 Limited, a newly incorporated company owned by funds managed by Bridgepoint Advisors II Limited, for a cash consideration of £24.9m payable upon completion of this sale. Net cash expected by the Company is expected to be around £27.0m. The disposal strengthens the balance sheet and enables the Group to accelerate organic and inorganic growth initiatives.

Artemis Resources 0.85p £14.0m (ARV.L)
The Australian-based mining exploration and development company report that a detailed strategic review of the Company's 100% owned Paterson Gold Project in Western Australia. A new priority target has been identified by a single station gravity anomaly, located ~2.5km from the Apollo Prospect. The depth of cover is unknown but represents a walk up target that warrants further exploration activity. Project located adjacent to Newmont/ Greatland Gold tier 1 discovery Havieron deposit containing over 6.5m oz Au. The Company is open to options to advance project including joint ventures and third party funding.

Avingtrans 360p £118.4m (AVG.L)
The international engineering group which designs, manufactures and supplies original equipment to the energy, medical and industrial sectors, announces its interim results for the six months ended 30 November 2023. Group revenue increased by 30.4% to £65.2m (2023 H1: £50.0m), as a result Adj.EBITDA increased by 14.1% to £7.3m. Adj. Profit before tax of £4.4m (2023 H1: £4.0m), and net debt at 30 November 2023 of £2.2m (31 May 2023: £13.0m net cash). Driven by investment in Slack & Parr, acquisition of the remaining 82% of Adaptix and ongoing investment in Magnetica. The Group is trading in line with management expectations and has good visibility over H2 FY24 revenue and profits.

Bradda Head Lithium 1.6p £6.2m (BHL.L)
The North America-focused lithium development group, announces finalisation of the land exchange over the unpatented lode claims at the Wikieup clay project in Western Arizona. Bradda Head will retain 66 new claims equating to 1,302 acres (5.27 km2), which the Company staked in early 2019. In turn, Bradda has transferred 55 unpatented lode claims to Arizona Lithium's subsidiary, Big Sandy Inc., to the amount of roughly 1,136 acres (4.60 km2), per the terms of this settlement. The new ground will be explored with geological mapping and surface sampling for opportunities, developing priority drill targets potentially for later in year.

EnSilica 67.5p £55.4m (ENSI.L)
A chip maker of mixed signal ASICs (Application Specific Integrated Circuits), announces that it has secured a order for the tape-out of a custom ASIC from a major electronics manufacturer headquartered in the US, worth c.US$20m in revenue for the calendar years 2025 and 2026 (Supply Win). This Supply Win, which was gained in part through the Company's global engineering and support team, alongside its extensive expertise with digital, analogue and radio frequency chips, is the first order from the US for manufacturing-only services utilising EnSilica's new silicon foundry channel partner.

Image Scan Holdings 1.05p £1.4m (IGE.L)
A specialist in the field of real-time X-ray imaging for the security and industrial inspection markets provides a trading update. The ThreatScan®-AS2 product was launched at the Middle Eastern Security Exhibition and the Company announces new orders for its Axis-CXi, expanded into new territories, including Spain and Switzerland. The Company has attended European and Middle Eastern demonstrations with new portable products and product combinations. The board are looking to create strategic opportunities to expand the business through partnerships and acquisitions.

Kibo Energy* 0.04p £1.7m (KIBO.L)
The renewable energy-focused development company, announces that its subsidiary Mast Energy Developments PLC (MED), a UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market has announced a new strategic funding partner & funding agreement, a new Capacity Market contract and termination of the Proventure joint venture agreement. Noting that the Funding Agreement described is with RiverFort Global Opportunities PCC Limited (RiverFort), an 11.68% shareholder in Kibo and MED, a subsidiary of Kibo.

Trellus Health 4p £6.5m (TRLS.L)
A digital health company providing scientifically validated, value-based solutions and services for chronic health conditions announces it has signed an agreement with a large US health plan, focused on Inflammatory Bowel Disease (IBD) condition management. The agreement is intended to run for up to twenty-one months, during which time members of the health plan with IBD that are receiving care in two US states will be eligible for inclusion in the Trellus ElevateIBD program.

Verditek 0.105p £0.6m (VDTK.L)
The clean technology company behind the development and production of lightweight, flexible solar panels, announces that it has entered into a conditional sale and purchase agreement to dispose of its solar business, to Verditek Solar Limited, a newly incorporated company owned and incorporated by the Company's bondholders for £528.3k. Subject to Completion, the resignation of each of the current directors, being The Rt Hon. Lord David Willetts, Robert Richards and George Katzaros and the proposed appointment of Bob Holt and John Charlton as directors of the Company. Bob Holt has agreed to assist the Company in procuring subscribers for 400 million new ordinary shares in the capital of the Company at 0.075p per share (up to £300k), Further details of a proposed fundraising to raise approximately £1.5m by the issue of new ordinary shares in the capital of the Company at 0.075p per share will be announced in due course.

28 February 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram